INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,618,328 | -36.0% | 741,377 | -22.2% | 0.04% | -35.5% |
| Q2 2023 | $60,333,955 | +118.5% | 952,842 | +86.9% | 0.06% | +106.7% |
| Q1 2023 | $27,611,302 | +1.6% | 509,904 | -0.7% | 0.03% | 0.0% |
| Q4 2022 | $27,174,420 | +66.8% | 513,500 | +46.7% | 0.03% | +57.9% |
| Q3 2022 | $16,289,000 | -15.7% | 350,078 | +3.4% | 0.02% | -17.4% |
| Q2 2022 | $19,331,000 | -13.4% | 338,661 | -7.1% | 0.02% | +9.5% |
| Q1 2022 | $22,311,000 | +177.5% | 364,618 | +137.4% | 0.02% | +200.0% |
| Q4 2021 | $8,039,000 | +309.7% | 153,587 | +219.6% | 0.01% | +250.0% |
| Q2 2021 | $1,962,000 | -51.8% | 48,063 | -59.9% | 0.00% | -50.0% |
| Q1 2021 | $4,072,000 | +4.2% | 119,999 | -2.4% | 0.00% | 0.0% |
| Q4 2020 | $3,908,000 | -45.5% | 122,903 | -56.0% | 0.00% | -42.9% |
| Q3 2020 | $7,175,000 | +21.0% | 279,603 | +21.0% | 0.01% | -12.5% |
| Q2 2020 | $5,932,000 | +63.2% | 231,085 | -2.3% | 0.01% | +60.0% |
| Q1 2020 | $3,635,000 | -62.4% | 236,447 | -16.0% | 0.01% | -54.5% |
| Q4 2019 | $9,656,000 | +463.4% | 281,413 | +22.6% | 0.01% | +450.0% |
| Q3 2019 | $1,714,000 | -62.8% | 229,526 | -35.3% | 0.00% | -66.7% |
| Q2 2019 | $4,607,000 | +21.1% | 354,888 | +13.7% | 0.01% | +20.0% |
| Q1 2019 | $3,803,000 | +11.8% | 312,258 | +4.6% | 0.01% | +25.0% |
| Q4 2018 | $3,401,000 | -42.1% | 298,571 | +10.2% | 0.00% | -42.9% |
| Q3 2018 | $5,877,000 | +36.8% | 270,813 | +11.4% | 0.01% | +40.0% |
| Q2 2018 | $4,295,000 | -8.3% | 243,070 | +9.2% | 0.01% | -16.7% |
| Q1 2018 | $4,685,000 | +748.7% | 222,571 | +483.3% | 0.01% | +500.0% |
| Q4 2017 | $552,000 | +16.5% | 38,155 | +30.7% | 0.00% | 0.0% |
| Q1 2017 | $474,000 | -73.5% | 29,192 | -75.3% | 0.00% | -66.7% |
| Q4 2016 | $1,786,000 | +217.2% | 118,390 | +220.7% | 0.00% | +200.0% |
| Q3 2016 | $563,000 | -78.8% | 36,921 | -46.0% | 0.00% | -80.0% |
| Q2 2016 | $2,656,000 | +291.7% | 68,412 | +443.0% | 0.01% | +400.0% |
| Q4 2015 | $678,000 | -73.7% | 12,600 | -80.4% | 0.00% | -75.0% |
| Q3 2015 | $2,578,000 | +108.6% | 64,378 | +66.4% | 0.00% | +100.0% |
| Q2 2015 | $1,236,000 | – | 38,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |